Trending eight years of in Vitro activity of Ertapenem and comparators against Escherichia coli from intra-abdominal infections in north America-SMART 2002-2009

Journal of Chemotherapy

Volumn 23, Issue 5, 2011, Pages 266-272

  Hawser, S P ^a   Badal, R E ^b   Bouchillon, S K ^b   Hoban, D J ^b  

^a International Health Management Associates Europe Sàrl   (Switzerland)

^b International Health Management Associates   (United States)

Author keywords

Ertapenem; Escherichia coli; Intra abdominal; North America; SMART; Susceptibility; Trends

Indexed keywords

AMIKACIN; CARBAPENEM; CARBAPENEM DERIVATIVE; CEFEPIME; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; ERTAPENEM; IMIPENEM; LEVOFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BETA LACTAM; BETA LACTAMASE;

ABDOMINAL INFECTION; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; DISEASE SURVEILLANCE; ESCHERICHIA COLI INFECTION; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; HUMAN; IN VITRO STUDY; INFECTION RATE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NORTH AMERICA; TREND STUDY; DRUG EFFECT; ENZYMOLOGY; ESCHERICHIA COLI; HEALTH SURVEY; ISOLATION AND PURIFICATION; METABOLISM; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MULTIDRUG RESISTANCE; PERITONEAL CAVITY;

ABDOMINAL CAVITY; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; BETA-LACTAMS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HUMANS; INTRAABDOMINAL INFECTIONS; MICROBIAL SENSITIVITY TESTS; NORTH AMERICA; POPULATION SURVEILLANCE;

EID: 84857700015     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/joc.2011.23.5.266     Document Type: Article

References (21)

1. Kirkland KB, Briggs JP, Trivette SHL, Wilkinson WE, Sexton DJ. The impact of surgical site infections in the 1990s: attributable mortality, excess length of hospitalization, and extra costs. Infect Control Hosp Epidemiol 1999; 20: 725-730.
2. Wong ES. The price of a surgical site infection: more than just excess length of stay. Infect Control Hosp Epidemiol 1999; 20: 722-724.
3. Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJ, Baron EJ, et al. Diagnosis and Management of Complicated intraabdominal infection in Adults and Children: Guidelines by the surgical infection society and the infectious Diseases society of America. Clin infect Dis 2010; 50: 133-150.
4. Hirsch EB, Tam VH. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J Antimicrob Chemother 2010; 65: 1119-1124.
5. Livermore DM, Canton R, Gniadkowski M, nordmann P, Rossolini GM, Arlet G, et al. CTx-M: changing the face of EsBLs in Europe. J Antimicrob Chemother 2007; 59: 165-174.
6. Woodford N, Dallow, Hill RL, Palepou MF, Pike R, Ward ME, et al. Ertapenem resistance among Klebsiella and Enterobacter submitted in the UK to a reference laboratory. Int J Antimicrob Agents 2007; 29: 456-459.
7. Woodford N, Zhang J, Warner M, Kaufmann ME, Matos J, Macdonald A et al. Arrival of Klebsiella pneumoniae producing KPC carbapenemase in the United Kingdom. J Antimicrob Chemother 2008; 62: 1261-126.
8. Livermore DM. The impact of carbapenemases on antimicrobial development and therapy. Curr Opin investig Drugs 2002; 3: 218-224.
9. Srinivasan A, Patel JB. Klebsiella pneumoniae carbapenemase-producing organisms: an ounce of prevention really is worth a pound of cure. Infect Control Hosp Epidemiol 2008; 29: 1107-1109.
10. Walsh TR, Toleman MA, Poirel L et al. Metallo-beta-lactamases: the quiet before the storm? Clin Microbiol Rev 2005; 18: 306-325.
11. Woodford N, Fagan EJ, Ellington MJ. Multiplex PCR for rapid detection of genes encoding CTx-M extended-spectrum (beta)-lactamases. J Antimicrob Chemother 2006; 57: 154-155.
12. Clinical and Laboratory standards institute. 2009. Methods for Dilution Antimicrobial susceptibility Tests for Bacteria That Grow Aerobically; Approved standard-Eighth Edition, in Document M7-A8. Clinical Laboratory standards institute (CLsi), 940 West Valley Road, suite 1400, Wayne, Pennsylvania 19087-1898 UsA.
13. Clinical and Laboratory standards institute. 2010. Performance standards for Antimicrobial susceptibility Testing, Twentieth informational supplement Updated, Document M100-s20-U. Clinical Laboratory standards institute (CLsi), 940 West Valley Road, suite 1400, Wayne, Pennsylvania 19087-1898 UsA.
14. Hawser SP, Bouchillon SK, Hoban DJ, Badal DE. Epidemiologic trends, occurrence of extended-spectrum-beta-lactamase production, and performance of ertapenem and comparators in patients with intra-abdominal infections: analysis of global trend data from 2002-2007 from the sMART study. Surg Infect 2010; 11: 371-378.
15. Hawser SP, Bouchillon SK, Hoban DJ, Cantó R, Baquero F. Incidence and antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae with extended-spectrum beta-lactamases in community-and hospital-associated intra-abdominal infections in Europe: results of the 2008 study for Monitoring Antimicrobial Resistance Trends (sMART). Antimicrob Agents Chemother 2010; 54: 3043-3046.
16. Hoban DJ, Bouchillon SK, Hawser SP, Badal RE, Labombardi VJ, DiPersio J. Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United states, 2007 - 2008: results of the study for Monitoring Antimicrobial Resistance Trends (sMART). Antimicrob Agents Chemother 2010; 54: 3031-3034.
17. Hsueh PR, Badal RE, Hawser SP, Hoban DJ, Bouchillon SK, Ni Y, et al. Epidemiology and antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region: 2008 results from SMART (study for Monitoring Antimicrobial Resistance Trends). Int J Antimicrob Agents 2010; 36: 408-414.
18. Clinical and Laboratory standards institute. 2010. Performance standards for Antimicrobial susceptibility Testing, Twentieth informational supplement, Document M100-s20. Clinical Laboratory standards institute (CLSI), 940 West Valley Road, suite 1400, Wayne, Pennsylvania 19087- 1898 USA.
19. Schwaber MJ, Carmeli Y. Carbapenem-resistant Enterobacteriaceae: a potential threat. J Amer Med Assoc 2008; 300: 2911-2913.
20. Wilcox MH. The tide of antimicrobial resistance and selection. Int J Antimicrob Agents. 2009;34 (suppl 3):s6-10.
21. Bradford PA, Weaver-Sands DT, Petersen PJ. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections. Clin Infect Dis 2005; 41 (suppl 5): s315-s322.